

18 Jul 2021 |

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: pharma's Q2 prospects; Bayer's plans for the US launch of its CKD drug; big tobacco takes further steps into healthcare; KRAS's emergence in oncology amid ongoing challenges; and tips for European biotech fundraising.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 16 July 2021, including: pharma's Q2 prospects; [Bayer AG](#)'s plans for the US launch of its CKD drug; big tobacco takes further steps into healthcare; KRAS's emergence in oncology amid ongoing challenges; and tips for European biotech fundraising.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Pharma Is Poised For A COVID-19 Recovery; Will Q2 Deliver?](#)" - Scrip, 13 Jul, 2021.)

(Also see "[Bayer Focusing On Early CKD Testing In Kerendia US Launch](#)" - Scrip, 12 Jul, 2021.)

(Also see "[Philip Morris Rebuts 'Cynical' Claims About £1bn Vectura Buy](#)" - Scrip, 9 Jul, 2021.)

(Also see "[KRAS Inhibitors Show Promise But Long Road Ahead, Say Experts](#)" - Scrip, 14 Jul, 2021.)

(Also see "[Fundraising Tips From The Top Of European Biotech](#)" - Scrip, 12 Jul, 2021.)

[Click here to explore this interactive content online](#) ✎